Dr. Donald Berry named amongst Thomson Reuters Highly Cited Researchers

Dr. Donald Berry has been named amongst Thomson Reuters Highly Cited Researchers in recognition of ranking among the top 1% of researchers for most cited documents, in their specific field (Clinical Medicine).

In further recognition of Dr. Berry's accomplishments, he has been listed in the "The World's Most Influential Scientific Minds: 2014".

The direct link to this report can be found on ScienceWatch.com at:  http://sciencewatch.com/grr/presenting-highly-cited-researchers

Dr. Berry's announcement letter from Thomson Reuters can be found here along with his certificate commemorating the Highly Cited Researcher distinction.

 

 

 

 

 

 

More Recent News

February 2024 QUOTES Webinar

Berry Consultants will be hosting a webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value of a drug development program using the software QUOTES (Quantification and Optimization of Trial Expectations Simulator).

Blog: Precision Promise Adaptive Platform Trial update

Blog by: Kert Viele News from the Precision Promise platform trial. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise Precision Promise is an adaptive platform trial investigating potential therapies for pancreatic cancer,

January 2024 FACTS Webinar

The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.

Blog: Comments on the draft FDA master protocol guidance

Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and